Swiss Medical Device Maker Ypsomed Sells Diabetes Business in CHF420 Million Deal
Bern-based Ypsomed announces sale of its diabetes care division to TecMed for CHF420 million, marking major shift in Swiss medical device industry.

Key Takeaways
- Ypsomed is selling its diabetes care division to TecMed
- The deal is valued at CHF420 million ($517 million)
- The transaction is expected to complete in second half of 2025
- The sale proceeds will finance expansion of injection systems business
By The Numbers
They Said
"Proceeds from the sale will finance the expansion of the injection systems business"